Physician profile
Rabih C Fahed
NPI 1043488844
$294,122.34
in general payments reported to CMS, 2019-2025
64 companies · $16K in 2025
The $16K reported for 2025 was more than what 92% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88K · 2020: $38K · 2021: $27K · 2022: $49K · 2023: $53K · 2024: $23K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $56K · Consulting Fee: $29K · Travel and Lodging: $5,368 · Food and Beverage: $3,047 · Education: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $55,610.00 |
| Consulting Fee | $28,832.06 |
| Travel and Lodging | $5,368.00 |
| Food and Beverage | $3,047.32 |
| Education | $197.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $147,918.57 | 2019-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $48,703.40 | 2019-2025 | Imfinzi, Calquence, Lynparza |
| Celgene Corporation | $21,466.83 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $16,440.55 | 2021-2023 | Libtayo |
| Seagen INC. | $10,228.26 | 2019-2025 | Adcetris |
| Incyte Corporation | $9,770.68 | 2019-2023 | Jakafi |
| Genzyme Corporation | $6,277.30 | 2019-2023 | |
| Exelixis INC. | $4,916.07 | 2019-2024 | Cabometyx |
| Dova Pharmaceuticals | $4,290.60 | 2020 | |
| Athenex Pharmaceutical Division, LLC | $4,175.00 | 2020-2021 | |
| Beigene USA, INC. | $2,450.00 | 2022-2024 | Brukinsa |
| Abbvie INC. | $2,433.97 | 2019-2025 | |
| Janssen Biotech, INC. | $1,981.43 | 2019-2025 | Carvykti, Tecvayli, Darzalex |
| Daiichi Sankyo INC. | $1,669.76 | 2021-2022 | |
| Karyopharm Therapeutics INC. | $1,569.63 | 2020-2025 | Xpovio |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rabih Fahed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.